Alembic Pharmaceuticals released its investor presentation regarding the unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation details the company’s performance in international generics, API sales, branded formulations, and key product launches. Total revenue increased by 17% in Q3 2026 compared to Q3 2025, reaching ₹954 Crs.
International Generics Performance
Alembic Pharmaceuticals reported growth in its international generics business. Key highlights include:
- USA Direct: Sales increased by 7%, reaching ₹478 Crs in Q3 FY26.
- Canada: Achieved a 32% growth, with sales of ₹93 Crs.
- Australia: Experienced substantial growth of 65%, with sales totaling ₹103 Crs.
- Europe & ROW: Sales grew by 28%, reaching ₹198 Crs.
For the nine months ended December 2025, USA sales increased 13% YTD, while EROW increased 30% YTD.
API Sales Overview
Alembic’s API (Active Pharmaceutical Ingredients) business also showed positive results:
- Q3 FY26 Total API Sales: ₹263 Crs, a 2% increase compared to Q3 FY25.
- Europe: Sales increased by 17%, reaching ₹49 Crs.
Key growth drivers include Azithromycin and Leflunomide.
YTD Dec’25 API sales totaled ₹837 Crs, a 6% increase.
US Launches
Alembic has been actively launching products in the US market:
- Cumulative Launches till FY’26: 172 products.
- Planned Launches in Q4’26: 7 products, including Loteprednol & Tobramycin oph. Suspension and Dexlansoprazole DR capsules.
ANDA Filings and Approvals
As of YTD Dec’25, Alembic has made significant progress in ANDA (Abbreviated New Drug Application) filings and approvals:
- Total ANDA Filed: 270
- Final Approvals: 194
- Final Approvals during FY26: 18
Branded Formulations (India)
The Indian branded formulations business also contributed to the company’s growth. Q3 FY26 sales were ₹652 Cr, a 6% increase YOY. Key therapy areas included Gynecology (₹83 Cr) and Cardiology (₹78 Cr). For 9M FY26 branded formulation sales were ₹1,890 Cr, a 5% increase YOY.
Source: BSE
